ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates
focused on the prevention and treatment of serious infectious and
other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at
the 7th Annual OneMedForum San Francisco 2014 conference next week
in San Francisco, as follows:
Date: Tuesday, January 14,
2014
Time: 11:30 a.m.
(PT)/2:30 p.m. (ET)
Location: The Westin San Francisco Market Street Hotel
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the internet at
http://onemedplace.com/forum/webcast/. After the presentation, a
replay will be archived and accessible for 30 days at the same
website.
(Logo:
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of product candidates for
serious infectious and other diseases. Synthetic Biologics is
developing oral treatments targeting archaea, a non-bacterial
intestinal form of life increasingly associated with chronic
diseases such as irritable bowel syndrome (IBS), obesity and type 2
diabetes, an oral biologic to protect the gastrointestinal
microflora from the effects of IV antibiotics for the prevention of
C. diff infection, a series of monoclonal antibodies (mAbs)
for the treatment of Pertussis and Acinetobacter infections,
and a biologic targeted at the prevention and treatment of IBS. In
addition, the Company is developing an oral estriol drug candidate
for the treatment of relapsing-remitting multiple sclerosis (MS)
and cognitive dysfunction in MS (with results of an ongoing 164
subject, 15 center, two-year, double blind, placebo controlled,
Phase II relapsing-remitting MS clinical trial expected to be
announced during the first half of 2014). For more information,
please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.